Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Los términos de búsqueda han de ser en inglés.

Native therapeutic targets and antigens for drug and vaccine discovery in Horizon Europe Health calls

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TOFR20210421001
Publicado:
29/04/2021
Caducidad:
30/04/2022
Resumen:
The French company develops new approaches to isolate full-length and native membrane therapeutic targets with the highest purity levels. The company produces its own pipeline of medically relevant targets and uses its technology platform for other companies that need to identify, extract and purify membrane proteins. The company is looking for academic partners to prepare a joint proposal to apply for European funding.

Details

Tittle:
Native therapeutic targets and antigens for drug and vaccine discovery in Horizon Europe Health calls
Summary:
The French company develops new approaches to isolate full-length and native membrane therapeutic targets with the highest purity levels. The company produces its own pipeline of medically relevant targets and uses its technology platform for other companies that need to identify, extract and purify membrane proteins. The company is looking for academic partners to prepare a joint proposal to apply for European funding.
Description:
The company has developed an approach that provides life science partners with the opportunity to work with high-quality and reliable targets or antigens, compatible with all applications and in all areas (human, animal and plant).
This includes developing antibodies and/or discovering drug candidates through structure-based drug design (X-ray and Cryogenic electron microscopy) or high-throughput screening assays.
The platform developed by the company also enables the formulation of new vaccines including against COVID-19.

The company is willing to further develop its technology by participating in a European call for proposal.
The following topics have been identified but the company is open to other topics where its technology could be useful:
- HORIZON-HLTH-2021-STAYHLTH-01-02 : "Towards a molecular and neurobiological understanding of mental health and mental illness for the benefit of citizens and patients"
- HORIZON-HLTH-2022-DISEASE-06-02-two-stage : "Pre-clinical development of the next generation of immunotherapies for diseases or disorders with unmet medical needs"
- HORIZON-HLTH-2022-DISEASE-06-03-two-stage "Vaccines 2.0 - Developing the next generation of vaccines"
- HORIZON-HLTH-2022-DISEASE-06-04-two-stage "Development of new effective therapies for rare diseases"

Research or Technical cooperation agreement would be concluded between the French and SME and academic partners
Advantages and Innovations:
Preparing high quality therapeutic targets for making the best drugs is a challenge tackled by only a few contract research organisations. Membrane proteins represents more than 60% of the market.
The company´s major advantage is to be able to prepare all types of targets (G protein-coupled receptors -GPCR, ion channels, receptors, transporters and viral targets) for all markers (human, animal, crop science).
This very specific approach gives access to a bigger market whereas other players work mainly on GPCRs (<30% of the market).
Moreover, the platform developed by the company allows the preparation of fully native targets without modification of their primary structure, where other players mutate and truncate the targets to help their stabilization.
The company owns 8 patent families and has been involved in 28 international papers.
Stage of Development:
Already on the market
IPs:
Secret Know-how,Patent(s) applied for but not yet granted,Patents granted,Trade Marks,Exclusive Rights
CommeR Statunts Regarding IPR Status:
The company owns 8 patent families and was ranked one of the most innovative companies among FrenchTech cluster (according to Forbes mag. in 2018 and 2019)
The company has participated to 28 international papers, mostly as corresponding author, including one paper with Roche Pharmaceuticals and one with Astrazeneca.
Moreover, the company holds several presentations each year in particular at Discovery on Targets (Boston) and at the Protein Engineering Summit (USA), alone or invited by their partners.

Partner sought

Type and Role of Partner Sought:
The SME is looking for academics and R-Y-D institutions involved in target identification and membrane target validation (G protein-coupled receptors, ion channels, receptors, transporters and viral targets) in all therapeutic areas (oncology, Central nervous system disease, cardiovascular diseases, infectious diseases, ....) and for all life science fields (human, animal, crop science). Ideally partner sought is participating or piloting a Horizon Europe proposal and open to work with new partners. Research cooperation or technical ccoperation agreement would drive the collaboration.

Client

Type and Size of Client:
Industry SME 11-49
Already Engaged in Trans-National Cooperation:
Si
Languages Spoken:
English
French
German

Dissemination

Restrict dissemination to specific countries:
Austria, Belgium, Czech_Republic, Denmark, Finland, Germany, Greece, Italy, Luxembourg, Netherlands, Norway, Poland, Portugal, Spain, Sweden, Switzerland, United Kingdom

Keywords

Technology Keywords:
06002002 Biología celular y molecular
06002001 Bioquímica / biofísica
06002007 Ensayos in vitro, experimentos
06002004 Ingeniería de proteínas
06002005 Ingeniería genética